BioCentury
ARTICLE | Company News

Chroma, Macrophage deal

January 20, 2017 7:58 PM UTC

Chroma granted Macrophage worldwide rights to Chroma's Esterase Sensitive Motif (ESM) technology plus therapeutic assets in discovery, including a phosphoinositide 3-kinase (PI3K) inhibitor. ESM deliv...

BCIQ Company Profiles

Chroma Therapeutics Ltd.